Is the AstraZeneca vaccine row dividing the EU?

magine if AstraZeneca happened to be an American or Chinese company, and manufactured all of its Covid vaccines far away from the EU and Britain. The chances are that the stories about production problems, breaches of contract and export bans would not have acquired the heated, chauvinistic Brexity quality that they have in recent days. It would be much more of a business story than yet another episode of the Brexit saga. It would matter, but the focus would be on the prosaic aspects of contractual obligations, complex supply chains and the impact on public health.  

Instead, of course, with a somewhat similar set of rows about the Pfizer vaccine, it has been itself infected by the virus of populist nationalism. In some ways, this probably suits the European Union, to be seen to be standing up for Europe’s citizens and demanding its fair share, legally and morally. Who cares, on this reading, if the British got their big order in first? Any company is obliged to honour its obligations no matter when any order was placed. So the EU wants transparency, from AstraZeneca. The company is sticking to its “first come first served” policy.  

The EU’s subsequent proposal to require approval for vaccine exports to third countries (mainly Britain), looks illogical, and nationalistic, even if it is only part of a continuing struggle with a private sector pharma giant. Conveniently, though, it distracts from any criticism among the member states about the EU’s own mistakes, if any. This may not last.